Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) EBIT Margin: 2019-2025

Historic EBIT Margin for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to -107.87%.

  • Keros Therapeutics' EBIT Margin rose 1500992.00% to -107.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.67%, marking a year-over-year increase of 3135929.00%. This contributed to the annual value of -5,938.96% for FY2024, which is 10660475.00% up from last year.
  • Per Keros Therapeutics' latest filing, its EBIT Margin stood at -107.87% for Q3 2025, which was up 50.78% from -219.16% recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' EBIT Margin ranged from a high of 2,019,700.00% in Q3 2021 and a low of -541,000.00% during Q3 2023.
  • Over the past 3 years, Keros Therapeutics' median EBIT Margin value was -15,117.78% (recorded in 2024), while the average stood at -87,260.48%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 142,230,000bps in 2021, then slumped by 157,703,403bps in 2022.
  • Over the past 5 years, Keros Therapeutics' EBIT Margin (Quarterly) stood at -24.33% in 2021, then slumped by 157,703,403bps to -134.03% in 2022, then reached -32,486.01% in 2023, then soared by 3,073,539bps to -1,750.62% in 2024, then spiked by 1,500,992bps to -107.87% in 2025.
  • Its EBIT Margin was -107.87% in Q3 2025, compared to -219.16% in Q2 2025 and 71.97% in Q1 2025.